Zulresso Approval History
FDA Approved: Yes (First approved March 19, 2019)
Brand name: Zulresso
Generic name: brexanolone
Dosage form: Injection
Company: Sage Therapeutics
Treatment for: Postpartum Depression
Zulresso (brexanolone) is a gamma-aminobutyric acid A (GABAA) receptor positive allosteric modulator indicated for the treatment of postpartum depression (PPD).
Development History and FDA Approval Process for Zulresso
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.